Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Rapid Engraftment, Immune Cell Reconstitution and Sustained Donor Chimerism in Patients Receiving G-CSF Mobilized Peripheral Blood Stem Cells (PB-SC) from Related or Unrelated Donors Undergoing CD34 Enrichment with Mononuclear Cell (T cell) Addback in Children, Adolescents, and Adults with Malignant and Nonmalignant Diseases

Jordan Milner, Cydney Nichols, Janet Ayello, MS, MT(ASCP), Karen P. Seiter, MD, Delong Liu, MD PhD, Erin Morris, RN, BSN, Sandra Fabricatore, RN, PNP, MSN, Yaya Chu, PhD, Rosemarie Shaw, Carmella van de Ven, MA, Allyson M. Flower, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-137668

Published: 2020

Journal Articles

Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Yaya Chu, PhD, Julie-An Talano, MD, Lee Ann Baxter-Lowe, PhD, Carolyn A. Keever-Taylor, PhD, Erin Morris, RN, BSN, Harshini Mahanti, BS, MSCR, Janet Ayello, MS, MT(ASCP), Bryon Johnson, PhD, Rona Singer Weinberg, PhD, Qiuhu Shi, PhD, Theodore B. Moore, MD, Sandra Fabricatore, RN, PNP, MSN, Brenda J. Grossman, MD, Carmella van de Ven, MA, Shalini Shenoy, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140425

Published: 2020

Journal Articles

Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-g Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)

Allyson M. Flower, MD, Rachel Friedmann, DO, Janet Ayello, MS, MT(ASCP), Olivia Rigot, PhD, Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Meghan Sturhahn, RN, MSN, Elana Maryamchik, MD, Yongping Wang, MD, Lynn O'Donnell, PhD, Rolla Abu-Arja, MD, Dean Anthony Lee, MD PhD, Julie-An Talano, MD, Bryon Johnson, PhD, Nancy Bunin, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140834

Published: 2020

Journal Articles

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Anthony N. Audino, MD, Matthew J. Barth, MD, Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Jessica C. Hochberg, MD, Stanton Goldman, MD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 3963.

https://doi.org/10.1182/blood-2019-128580

Published: 2019

Journal Articles

Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Yaya Chu, PhD, Julie-An Talano, MD, Lee Ann Baxter-Lowe, PhD, Carolyn A. Keever-Taylor, PhD, Erin Morris, RN, BSN, Harshini Mahanti, BS, MSCR, Janet Ayello, MS, MT(ASCP), Rona Singer Weinberg, PhD, Qiuhu Shi, PhD, Theodore B. Moore, MD, Sandra Fabricatore, RN, PNP, MSN, Brenda J. Grossman, MD, Carmella van de Ven, MA, Shalini Shenoy, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 1990.

https://doi.org/10.1182/blood-2019-126757

Published: 2019

Journal Articles

Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD)

Blood (2018) 132 (Supplement 1): 162.

https://doi.org/10.1182/blood-2018-162

Published: 2018

Journal Articles

Promising Results at 1 Year Follow-up Following Familial Haploidentical (FHI) T-Cell Depleted (TCD) with CD34 Enrichment and T-Cell (CD3) Addback Allogeneic Stem Cell Transplantation in Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359)

Julie-An Talano, MD, Theodore B Moore, MD, Carolyn A. Keever-Taylor, DPhil, Shalini Shenoy, MD, Mark C. Walters, MD, Susan K Parsons, MD MRP, Allen J Dozor, MD, Deborah Friedman, MD, Qiuhu Shi, PhD, Suzanne Braniecki, PhD, Brenda J. Grossman, MD, Rona Singer Weinberg, PhD, Elliott Vichinsky, MD, Yaya Chu, PhD, Erin Morris, RN, BSN, Sandra Fabricatore, RN, PNP, MSN, Janet Ayello, MS, MT(ASCP), Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 4602.

https://doi.org/10.1182/blood.V130.Suppl_1.4602.4602

Published: 2017

Journal Articles

Polatuzumab Vedotin Alone or in Combination with Obinutuzumab Synergistically Enhances I n-Vitro Cytotoxicity and Cytokine Release Against CD20+/ CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL)

Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Christian Klein, PhD, Dean Anthony Lee, MD PhD, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 1540.

https://doi.org/10.1182/blood.V130.Suppl_1.1540.1540

Published: 2017

Journal Articles

Obinutuzumab (GA101) Significantly Inhibits Cell Proliferation and Induces Programmed Cell Death in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May be a Future Targeted Agent for the Treatment of PMBL

Changhong Yin, MS, Sanghoon Lee, PhD MSc., Timmy O'Connell, MS, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2014) 124 (21): 4492.

https://doi.org/10.1182/blood.V124.21.4492.4492

Published: 2014

Journal Articles

A Comparative Global Phosphoproteomics Analysis of Obinutuzumab (GA101) Versus Rituximab (RTX) Against RTX Sensitive and Resistant Burkitt Lymphoma (BL) Demonstrates Differential Phosphorylation of Signaling Pathways Proteins

Aradhana Awasthi, PhD, Delphine C.M. Rolland, PharmD, PhD, Mona Elmacken, MD, Christopher Reggio, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Venkatesha Basrur, PhD, Kevin Conlon, MS, Damian Fermin, PhD, Matthew J. Barth, MD, Kojo S.J. Elenitoba-Johnson, MD, Megan S Lim, MD PhD, Mitchell S. Cairo, MD

Blood (2014) 124 (21): 5481.

https://doi.org/10.1182/blood.V124.21.5481.5481

Published: 2014

Journal Articles

Familial Haploidentical (FHI) T-Cell Depleted (TCD) with T-Cell Addback Stem Cell Transplantation for Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359)

Blood (2014) 124 (21): 2582.

https://doi.org/10.1182/blood.V124.21.2582.2582

Published: 2014

Journal Articles

Effectively Targeting Burkitt Lymphoma By Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer Cells Combined with a Histone Deacetylase Inhibitor, Romidepsin in-Vitro and in Humanized NSG Mice

Yaya Chu, PhD, Ashlin Yahr, Janet Ayello, MS, MT(ASCP), Mitchell S. Cairo, MD

Blood (2014) 124 (21): 1108.

https://doi.org/10.1182/blood.V124.21.1108.1108

Published: 2014

Journal Articles

Comparative Study of Obinutuzumab (GA101) Vs. Rituximab Against CD20 + rituximab-Sensitive and -Resistant Burkitt (BL) and Acute Lymphoblastic Leukemia (B-ALL): Potential Targeted Therapy in Patients with High Risk BL and Pre-B-ALL

Aradhana Awasthi, PhD, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mona Elmacken, MD, Christopher Reggio, Matthew J. Barth, MD, Mitchell S. Cairo, MD

Blood (2014) 124 (21): 2251.

https://doi.org/10.1182/blood.V124.21.2251.2251

Published: 2014

Journal Articles

Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer (NK) Cells Significantly Mediate Burkitt Lymphoma (BL) Regression and Improve Survival In Human BL Xenografted NSG Mice

Yaya Chu, PhD, Ashlin Yahr, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Xianzheng Zhou, MD, PhD, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 3263.

https://doi.org/10.1182/blood.V122.21.3263.3263

Published: 2013

Journal Articles

Obinutuzumab (GA101) Significantly Improves Survival In CD20 Positive Pre-B Cell Lymphoblastic Leukemia (pre-B-ALL) Xenograft Models Compared To Rituximab (RTX): Potential Targeted Therapy In Patients With High Risk Pre-B-ALL

Aradhana Awasthi, Ph.D, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Stefan Hovy, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 3068.

https://doi.org/10.1182/blood.V122.21.3068.3068

Published: 2013

Journal Articles

Transcription Activator Like Effector Nucleases (TALENs) Mediated CD20 Gene Knockout Burkitt Lymphoma Model

Sanghoon Lee, PhD, MSc, Changhong Yin, MS, Janet Ayello, MS, MT(ASCP), Michael Genualdi, MS, Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 4883.

https://doi.org/10.1182/blood.V122.21.4883.4883

Published: 2013

Journal Articles

Obinutuzumab (GA101), a Novel Type II Glycoengineered CD20 Antibody, Significantly Induced Programmed Cell Death In Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May Be a Future Potential Targeted Agent For The Treatment Of PMBL

Changhong Yin, MS, Timmy O'Connell, MS, Janet Ayello, MS, MT(ASCP), Carmella vande Ven, MA, Sanghoon Lee, PhD, MSc, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 5146.

https://doi.org/10.1182/blood.V122.21.5146.5146

Published: 2013

Journal Articles

Exogenous Overexpression Of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells To RTX Induced Apoptosis

Sanghoon Lee, PhD, MSc, Changhong Yin, MS, Janet Ayello, MS, MT(ASCP), Timmy O'Connell, MS, Carmella van de Ven, MA, Miguel Muniz, AAS, Matthew J. Barth, MD, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 2503.

https://doi.org/10.1182/blood.V122.21.2503.2503

Published: 2013

Journal Articles

Overexpression Of Deleted In Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 May Be a Tumor Suppressor Gene In a Subset Of Patients With PMBL

Changhong Yin, MS, Tae-Hoon Chung, PhD, Janet Ayello, MS, MT(ASCP), Tae-Hyun Park, MS, Carmella van de Ven, MA, Mitchell S. Cairo, MD, Sanghoon Lee, Ph.D, MSc.

Blood (2013) 122 (21): 3852.

https://doi.org/10.1182/blood.V122.21.3852.3852

Published: 2013

Journal Articles

Sequence-Specific Talens-Induced DLEU1 Gene Disruption Significantly Suppresses Apoptosis and Increases Phosphorylation Of AKT and Ikba In Pediatric Burkitt Lymphoma (PBL): DLEU1 May Act As a Tumor Suppressor Gene In PBL

Sanghoon Lee, PhD, MSc, Changhong Yin, MS, Timmy O'Connell, MS, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 1279.

https://doi.org/10.1182/blood.V122.21.1279.1279

Published: 2013

NARROW

Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD)

Promising Results at 1 Year Follow-up Following Familial Haploidentical (FHI) T-Cell Depleted (TCD) with CD34 Enrichment and T-Cell (CD3) Addback Allogeneic Stem Cell Transplantation in Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359)

Polatuzumab Vedotin Alone or in Combination with Obinutuzumab Synergistically Enhances I n-Vitro Cytotoxicity and Cytokine Release Against CD20+/ CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL)

Obinutuzumab (GA101) Significantly Inhibits Cell Proliferation and Induces Programmed Cell Death in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May be a Future Targeted Agent for the Treatment of PMBL

A Comparative Global Phosphoproteomics Analysis of Obinutuzumab (GA101) Versus Rituximab (RTX) Against RTX Sensitive and Resistant Burkitt Lymphoma (BL) Demonstrates Differential Phosphorylation of Signaling Pathways Proteins

Familial Haploidentical (FHI) T-Cell Depleted (TCD) with T-Cell Addback Stem Cell Transplantation for Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359)

Effectively Targeting Burkitt Lymphoma By Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer Cells Combined with a Histone Deacetylase Inhibitor, Romidepsin in-Vitro and in Humanized NSG Mice

Comparative Study of Obinutuzumab (GA101) Vs. Rituximab Against CD20 + rituximab-Sensitive and -Resistant Burkitt (BL) and Acute Lymphoblastic Leukemia (B-ALL): Potential Targeted Therapy in Patients with High Risk BL and Pre-B-ALL

Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer (NK) Cells Significantly Mediate Burkitt Lymphoma (BL) Regression and Improve Survival In Human BL Xenografted NSG Mice

Obinutuzumab (GA101) Significantly Improves Survival In CD20 Positive Pre-B Cell Lymphoblastic Leukemia (pre-B-ALL) Xenograft Models Compared To Rituximab (RTX): Potential Targeted Therapy In Patients With High Risk Pre-B-ALL

Transcription Activator Like Effector Nucleases (TALENs) Mediated CD20 Gene Knockout Burkitt Lymphoma Model

Obinutuzumab (GA101), a Novel Type II Glycoengineered CD20 Antibody, Significantly Induced Programmed Cell Death In Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May Be a Future Potential Targeted Agent For The Treatment Of PMBL

Exogenous Overexpression Of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells To RTX Induced Apoptosis

Overexpression Of Deleted In Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 May Be a Tumor Suppressor Gene In a Subset Of Patients With PMBL

Sequence-Specific Talens-Induced DLEU1 Gene Disruption Significantly Suppresses Apoptosis and Increases Phosphorylation Of AKT and Ikba In Pediatric Burkitt Lymphoma (PBL): DLEU1 May Act As a Tumor Suppressor Gene In PBL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only